Dr. Marc Hedrick is the President and CEO at PLUS THERAPEUTICS, Inc. Previously, Dr. Hedrick served in a number of executive leadership roles including President, CEO, and Director at Cytori Therapeutics, Inc., and President and CEO of StemSource, Inc. Dr. Hedrick is a trained general, vascular, and plastic surgeon and former Associate Professor of Surgery and Pediatrics at the University of California, Los Angeles (UCLA). Dr. Hedrick also served as Co-Director of the Laboratory of Regenerative Bioengineering and Repair at UCLA. Dr. Hedrick obtained his MD from the University of Texas Southwestern Medical School, Dallas and a MBA from The Anderson School at UCLA in 2005.
Andrew Sims is Vice President and Chief Financial Officer at PLUS THERAPEUTICS, Inc. Mr. Sims arrived at Plus Therapeutics having previously held Chief Financial Officer roles at several private equity-backed companies. His focus has been on mergers and acquisitions, integrations, corporate capitalization, and building out and managing teams to support global growth. Previously, Mr. Sims was Partner at Mazars, a global accounting, advisory, audit, tax and consulting firm. Working from both the Oxford, England and New York offices, Mr. Sims audited and advised global public clients, including a variety of healthcare companies, with average annual revenues in excess of $1 billion. Further, he was the lead partner on over 50 acquisitions ranging from $5 million to $4 billion in purchase price. Mr. Sims is a native of the United Kingdom and is now a proud U.S. citizen. He is a Certified Public Accountant in the U.S. and a Chartered Accountant in England and Wales. He is a graduate of Buckingham University in the United Kingdom.
Norman LaFrance, MD is the Chief Medical Officer and Senior Vice President at PLUS THERAPEUTICS, Inc. He was previously Chief Medical Officer and Senior Vice President at Jubilant Pharma Ltd., responsible for all Pharma Medical & Regulatory Affairs activities.
>Prior to Jubilant Pharma, Ltd., Dr. LaFrance served as Global Chief Medical Officer at IBA Molecular from 2010 to 2012, and as Senior Vice President, Clinical Development and Chief Medical Officer at Molecular Insight Pharmaceuticals from 2007 to 2010. Prior to industry, Dr. LaFrance practiced medicine and held academic faculty appointments at Johns Hopkins University School of Medicine in the departments of medicine and radiology and the Department of Radiological Sciences in the John Hopkins School of Hygiene and Public Health. He is Double Board Certified with Fellowship status both in internal medicine and nuclear medicine, maintains active medical licensure in the U.S. along with active, professional society membership.
Dr. LaFrance received his Bachelor of Science and Master of Engineering degrees in nuclear engineering and science from Rensselaer Polytechnic Institute, and his medial degree from the University of Arizona, College of Medicine, Tucson.
Russ Havranek is the Vice President of Corporate Strategy and New Product Planning at PLUS THERAPEUTICS, Inc. He was previously Vice President of Global Marketing and Business Development at Cytori Therapeutics Inc. Mr. Havranek has 24 years of marketing, general management, and product development experience with major life science companies including Johnson & Johnson, Guidant Corporation (now Abbott), Genentech Inc. (now Roche), and Volcano Corporation (now Philips). Mr. Havranek received a MBA in Marketing from the Haas School of Business at the University of California, Berkeley, a MS in Bioengineering from Clemson University, and a BS in Biomedical Engineering from Northwestern University.
Cheri Rice is the Vice President of Product Development at PLUS THERAPEUTICS, Inc. She previously served in the same role at Cytori Therapeutics Inc. Prior to joining Cytori, she served as Vice President of Disposable Development for Volcano Corporation, a leading developer of intravascular ultrasound diagnostic equipment from June 2008 until May 2015. Prior to Volcano she worked her way up through the ranks at Abbott Vascular, ending her tenure as Manager of Process Development. She brings 27 years of Program Management and Engineering in experience to Plus Therapeutics. Ms. Rice has her bachelor’s degree in Mechanical Engineering from San Diego State University.